YLYin-Xiong Li

Yin-Xiong Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yin-Xiong Li has a total of 274 co-authors. Here are the top co-authors by number of shared publications:

  • Fan Yang

    Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

    36 shared publications
  • Yan Chen

    Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

    28 shared publications
  • Kai You

    Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, CAS Key Laboratory of Regenerative Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

    20 shared publications
  • Yingying Xu

    Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

    18 shared publications
  • Yuanqi Zhuang

    Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

    18 shared publications
  • Tingcai Pan

    Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

    16 shared publications

Latest Publications

  • Open Access

    Explainable Artificial Intelligence and Gene-Network Analysis Prioritise a TREM2/LGALS3/GPNMB Scar-Associated Macrophage Programme in Human Liver Cirrhosis

    by Shah Faisal, Muhammad Adeel Ejaz, Piniel Alphayo Kambey, Abdul Malik, Yin-Xiong Li

    Macrophages organise the fibrotic niche of liver cirrhosis. The scar-associated macrophage state is well described, but the genes that define it have rarely been ranked in an unbiased, model-based way, and the statistical limits of such re-analyses are seldom reported. Here we set out to re-derive the scar-associated macrophage programme without supervision, to rank its constituent genes by convergent computational evidence, and to state explicitly what a cohort of this size can and cannot support. We re-analysed 58,358 single-cell transcriptomes from five uninjured and five cirrhotic human livers (GEO GSE136103; Edinburgh DataShare DS_10283_3433). After quality control, Harmony batch integration and Leiden clustering, the mononuclear-phagocyte compartment (9869 cells) was re-clustered. We applied donor-level compositional testing stratified within the CD45+/CD45− sorted fractions, donor-level pseudobulk differential expression, three classifiers with SHapley Additive exPlanations (SHAP) under donor-grouped cross-validation, transcription-factor differential expression, diffusion pseudotime, ligand–receptor modelling and CellOracle in silico perturbation. The donor, never the cell, was the unit of analysis for every condition comparison. A discrete macrophage cluster (390 cells; 60.5% cirrhotic; contributed by all 10 donors) carried a coherent lipid/scar programme comprising LGALS3, GPNMB, TREM2, CD9, FABP5, APOE, APOC1 and CTSD, and was recovered in all 22 clustering configurations tested. The integrated prioritisation was robust: seven genes remained in the top 20 in 100% of 1000 Dirichlet re-weightings. MAFB, MITF and TFEC were significantly enriched transcription factors, and pseudotime placed the state downstream of a monocyte root. Three findings temper these results. No lineage showed a significant compositional change after multiple-testing correction, and every test was underpowered for its observed effect. No gene reached significance in donor-level pseudobulk differential expression. Classifier performance of 0.99 reflects the circularity of predicting a cluster defined from the same matrix; the non-circular contrast of cirrhotic versus uninjured cells gave 0.61–0.65. Overall, a documented, fully reproducible framework re-derives and ranks a TREM2/LGALS3/GPNMB scar-associated macrophage programme and nominates galectin-3, GPNMB and the SPP1 axis as prioritised, clinically unproven candidates. The prioritisation is a hypothesis requiring independent, spatial, protein-level and functional validation.

  • Open Access

    ASGR1 Deficiency Promotes Liver Fibrosis by Enhancing Pro‐Inflammatory Arachidonic Acid Metabolism and ALP Secretion

    by Hui Zhu, Xin‐Ping Huang, Kai You, Yan Chen, Peng‐Hui Li, Jia‐Wang Tao, Xiao‐Rui Yu, Jie‐Hui Xu, Guo‐Sheng Xu, Yin‐Xiong Li

    Background: Asialoglycoprotein receptor 1 (ASGR1), a hepatocyte‐specific receptor, represents a potential therapeutic target for hypercholesterolemia. However, liver safety risks of ASGR1‐targeted therapies remain poorly characterized. This study aims to investigate the impact of ASGR1 deficency on liver fibrosis and its underlying mechanisms. Methods: ASGR1 knockout (ASGR1 −/− ) mice and wild‐type controls were subjected to carbon tetrachloride (CCl 4 ) administration or bile duct ligation (BDL) to induce liver fibrosis. Serum biomarkers, including alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST), were measured. Transcriptomic analysis was performed to identify altered pathways. Primary mouse hepatocytes, HepG2 cells, and hepatic stellate cells (HSCs) were used for in vitro mechanistic validation. Results: ASGR1 deficiency significantly exacerbates liver fibrosis in both CCl 4 ‐ and BDL ‐induced models and specifically induces an increase in serum alkaline phosphatase (ALP), which showed greater sensitivity than alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Mechanistic studies showed that ASGR1 loss led to a significant increase in the transcription and secretion of hepatic ALP. Transcriptomic analysis revealed that ASGR1 knockout mice not only disrupted bile acid metabolism but also upregulated the synthesis of arachidonic acid metabolites (e.g., PTGES, a key enzyme involved in pro‐inflammatory eicosanoid synthesis) and the pro‐fibrotic factor TGFβ1, collectively accelerating fibrosis. Importantly, Supernatants from ASGR1 −/− primary mouse hepatocytes and HepG2 cells, as well as exogenous ALP, directly activated hepatic stellate cells (HSCs), promoting their activation and α‐SMA expression. Conclusions: ASGR1 deficiency aggravates liver fibrosis, which is likely mediated through the “ASGR1‐arachidonic acid‐ALP” axis that enhances pro‐inflammatory eicosanoid production and ALP secretion. These findings highlight the liver‐specific safety risk of ASGR1 as a therapeutic target for lipid disorders and provide mechanistic and translational references for clinical safety monitoring of ASGR1‐targeted drugs.


  • Open Access

    Nurr1 deficiency orchestrates a coupled liver–gut pathological axis revealed by multi-omics and deep-learning histopathology

    by Shah Faisal, Ibad Ullah, Piniel Alphayo Kambey, Abdul Malik, Muhammad Adeel Ejaz, Sajjad Ali Shah, Yin-Xiong Li

    The nuclear receptor Nurr1 (NR4A2) is a transcriptional regulator of inflammatory homeostasis, but its systemic effects on orchestrating inter-organ communications are largely unknown. Here we show that Nurr1 haplo-insufficiency results in a lethal coupled disorder across the liver-gut axis. Using a CRISPR-Cas9 generated murine model, we find that metabolically-activated heterozygous deficiency of Nurr1 results in profound hepatocellular necrosis and marked hepatic activation of inflammatory and pro-fibrotic genes coupled with dysregulation of the intestinal barrier, and severe small-intestinal dysbiosis. Multi-omics integration reveals a highly penetrant transcriptional signature of this herein termed liver-gut disorder, achieving up to 0.950 accuracy (SVM-RBF, 10-fold cross-validation) in classifying genotypes from integrated multi-omics features. Notably, we also demonstrate that these gene level perturbations in Nurr1 haplo-insufficiency can be thought of as learnable tissue ‘morphologies’ detectable by AI. Next, we created deep convolutional neural networks that accurately classify genotype from routine histopathology. Our algorithm achieves 99.50% accuracy in classifying hepatic fibrosis (Sirius Red), 99.20% in liver inflammation (H&E) and 92.31% in intestine (H&E). We provide the first multi-omics phenotype of Nurr1 deficiency, revealing its pivotal regulatory role in coordinating liver-gut homeostasis, and establishing a histopathological AI-driven framework. Grad-CAM saliency analysis confirms biological interpretability. Translational relevance is supported by human transcriptomic data (E-GEOD-61260) showing concordant upregulation of COL1A1 (log 2 FC= + 0.725, p < 0.01), TGFB1 (+ 0.429, p < 0.05), and MMP9 (+ 0.969, p < 0.01) alongside reduced NR4A2/ NURR1 in human liver disease.


  • Open Access

    SOX4: A potential therapeutic target for liver disease

    by Penghui Li, Ao Wang, Fan Yang, Yan Chen, Yinxiong Li

  • Open Access

    An Integrated Single-Cell Atlas Reveals Hepatic Stellate Cell Heterogeneity and Spatiotemporal Dynamics after Liver Injury

    by Jiongliang Wang, Jiawang Tao, Cuicui Xia, Miaoxiu Tang, Andrei-Florian Stoica, Shengxian Yuan, Yinxiong Li, Lin Guo, Xiangqian Kong, Jie Wang

    Background: Hepatic stellate cells (HSCs) orchestrate fibrosis-free repair after acute liver injury (ALI) and sustain fibrogenesis in chronic liver injury (CLI). However, the heterogeneity and spatiotemporal dynamics of HSCs across these different injury models remain elusive. This study sought to construct a cross-etiological HSC atlas to delineate HSC states and transitions during liver injury. Methods: We integrated 86,072 single-cell transcriptomes from 84 mouse samples across four etiologies and validated findings using multi-omics data from 277 mouse and 798 human samples. Cellular dynamics were characterized through clustering, trajectory inference, spatial analysis, and multicellular coordination network analysis. Experimental validation included liver injury models and gain-of-functional assays in primary mouse HSCs and LX-2 cells. Results: We established a cross-etiological, spatiotemporally resolved HSC atlas comprising 11 subpopulations. Trajectory analysis delineated a continuous quiescence-activation-attenuation (QAA) trajectory, recapitulating the in vivo full spectrum of state transitions and being supported by sequential pathway activation validated in vitro . In ALI, HSCs spatiotemporally completed the QAA trajectory around injury zones, whereas collagen-producing S100a6 ⁺ HSCs pathologically accumulated in mouse and human CLI due to trajectory dysregulation. Notably, the atlas identified a previously unrecognized apoptosis-prone Mrc2 ⁺ HSC subtype strongly co-localized with p53 in both mice and humans. Overexpression of transcription factors confirmed that Hbp1 , Tbx20 , Atoh8 , and Plagl1 enriched in Mrc2 + HSCs promoted HSC apoptosis. Finally, we revealed the microenvironment of distinct cellular modules which coordinated HSC progression along the QAA trajectory. A 531-gene signature derived from the inflammatory-fibrotic cellular module significantly correlated with fibrosis stage and hepatocellular carcinoma risk in human cohorts. Conclusions: We established a comprehensive HSC atlas and delineates HSC heterogeneity and spatiotemporal dynamic across etiologies. Dysregulation of the QAA trajectory underlies fibrotic progression, providing a resource for identifying antifibrotic targets.

  • Open Access

    Novel prolyl endopeptidase inhibitor from Myricaria germanica alleviates steatohepatitis

    by Khair Ullah, Tasneef Azam, Abdul Sammad, Tanveer Ahmed, Abdul Wadood, Muhammad Fawad Ali, Ghulam M. Mushraf, Bina Shaheen Siddiqui, Yin-Xiong Li

    PREPi ((±)-2-pentacosylcyclohexanol) from Myricaria germanica inhibits prolyl endopeptidase, alleviating steatohepatitis via reduced oxidative stress and lipid accumulation in preclinical models.


  • Lhx2 specifically expressed in HSCs promotes liver regeneration and inhibits liver fibrosis

    by Jiawang Tao, Zichao Wu, Yanran Liang, Jiongliang Wang, Miaoxiu Tang, Sunan Huang, Fan Jiang, Guangqi Zhou, Lin Guo, Shengxian Yuan, et al.

    Background and Aims: Promoting liver regeneration while inhibiting fibrogenesis represented an attractive strategy for treating liver diseases, with HSCs being crucial to both processes. This study aimed to identify specific targets in HSCs that simultaneously facilitated regeneration and suppressed fibrosis, and elucidated their molecular mechanisms. Approach and Results: Through comparing acute and chronic liver injury mouse models induced by CCl4 injections, we revealed that HSCs exhibited dual functionality, expressing pro-regenerative and profibrogenic genes following injury. Analyzing RNA-seq data from primary HSCs of these models, along with publicly available single-cell RNA-seq data of HSCs, we identified transcription factor Lhx2, specifically expressed in HSCs, as a potential regulator of the dual functions. Notably, Lhx2 showed significantly higher expression in HSCs from healthy liver tissue compared to fibrotic liver, in both mouse and human models. Lhx2 knockdown impaired liver function recovery and cellular proliferation after acute liver injury. Consistent changes were observed in mice with HSC-specific Lhx2 overexpression. In addition, Lhx2 overexpression not only promoted hepatocyte proliferation but also exhibited an antifibrogenic function after chronic injury. Mechanistically, Lhx2 suppressed multiple functions of activated HSCs, including fibrogenesis, proliferation, and migration, and upregulated SMAD6 to block the TGF-β signaling pathway. Moreover, Lhx2 was an upstream regulator of various pro-regenerative factors, especially HGF, which is crucial for liver regeneration. Conclusions: We demonstrated that Lhx2 had pro-regenerative and antifibrogenic functions, and elucidated its regulatory mechanism. The study provided a potential target with dual effects for treating liver diseases.


  • Open Access

    Deficiency of ASGR1 Alleviates Diet-Induced Systemic Insulin Resistance via Improved Hepatic Insulin Sensitivity

    by Xiaorui Yu, Jiawang Tao, Yuhang Wu, Yan Chen, Penghui Li, Fan Yang, Miaoxiu Tang, Abdul Sammad, Yu Tao, Yingying Xu, et al.

    Background: Insulin resistance (IR) is the key pathological basis of many metabolic disorders. Lack of asialoglycoprotein receptor 1 (ASGR1) decreased the serum lipid levels and reduced the risk of coronary artery disease. However, whether ASGR1 also participates in the regulatory network of insulin sensitivity and glucose metabolism remains unknown.Methods: The constructed ASGR1 knockout mice and ASGR1-/- HepG2 cell lines were used to establish the animal model of metabolic syndrome and the IR cell model by high-fat diet (HFD) or drug induction, respectively. Then we evaluated the glucose metabolism and insulin signaling in vivo and in vitro.Results: ASGR1 deficiency ameliorated systemic IR in mice fed with HFD, evidenced by improved insulin intolerance, serum insulin, and homeostasis model assessment of IR index, mainly contributed from increased insulin signaling in the liver, but not in muscle or adipose tissues. Meanwhile, the insulin signal transduction was significantly enhanced in ASGR1-/- HepG2 cells. By transcriptome analyses and comparison, those differentially expressed genes between ASGR1 null and wild type were enriched in the insulin signal pathway, particularly in phosphoinositide 3-kinase-AKT signaling. Notably, ASGR1 deficiency significantly reduced hepatic gluconeogenesis and glycogenolysis.Conclusion: The ASGR1 deficiency was consequentially linked with improved hepatic insulin sensitivity under metabolic stress, hepatic IR was the core factor of systemic IR, and overcoming hepatic IR significantly relieved the systemic IR. It suggests that ASGR1 is a potential intervention target for improving systemic IR in metabolic disorders.


  • Open Access

    Transcriptome Analyses of Liver Sinusoidal Endothelial Cells Reveal a Consistent List of Candidate Genes Associated with Endothelial Dysfunction and the Fibrosis Progression

    by Penghui Li, Wenjie Xie, Hongjin Wei, Fan Yang, Yan Chen, Yinxiong Li

    Liver fibrosis is an important step in the transformation of chronic liver disease into cirrhosis and liver cancer, and structural changes and functional disorders of liver sinusoidal endothelial cells (LSECs) are early events in the occurrence of liver fibrosis. Therefore, it is necessary to identify the key regulatory genes of endothelial dysfunction in the process of liver fibrosis to provide a reference for the diagnosis and treatment of liver fibrosis. In this study, we identified 230 common differentially expressed genes (Co-DEGs) by analyzing transcriptomic data of primary LSECs from three different liver fibrosis mouse models (carbon tetrachloride; choline-deficient, l-amino acid-defined diet; and nonalcoholic steatohepatitis). Enrichment analysis revealed that the Co-DEGs were mainly involved in regulating the inflammatory response, immune response, angiogenesis, formation and degradation of the extracellular matrix, and mediating chemokine-related pathways. A Venn diagram analysis was used to identify 17 key genes related to the progression of liver cirrhosis. Regression analysis using the Lasso–Cox method identified genes related to prognosis among these key genes: SOX4, LGALS3, SERPINE2, CD52, and LPXN. In mouse models of liver fibrosis (bile duct ligation and carbon tetrachloride), all five key genes were upregulated in fibrotic livers. This study identified key regulatory genes for endothelial dysfunction in liver fibrosis, namely SOX4, LGALS3, SERPINE2, CD52, and LPXN, which will provide new targets for the development of therapeutic strategies targeting endothelial dysfunction in LSECs and liver fibrosis.